The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

StreamPlay Studio Ltd is engaged in the acquisition and development of an online gaming platform. The company is engaged in the development of online eSport and gaming tournament platform technology ...